IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis

Experimental Neurology

Volumn 211, Issue 1, 2008, Pages 14-24

  Liu, Ruolan ^a   Bai, Ying ^a,b,g   Vollmer, Timothy L ^a   Bai, Xue Feng ^c   Jee, Youngheun ^a,d   Tang, Yi yuan ^b   Campagnolo, Denise I ^a   Collins, Mary ^e   Young, Deborah A ^e   La Cava, Antonio ^f   Shi, Fu Dong ^a,b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d Jeju National University   (South Korea)

^e PFIZER INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DALIAN UNIVERSITY   (China)

Author keywords

Autoimmunity; CD4+CD25+ regulatory T cells; EAE; IL 21 receptor; NK cells

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 7; TRANSCRIPTION FACTOR FOXP3;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; ANTIGENS, SURFACE; CELL PROLIFERATION; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GLYCOPROTEINS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-21; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 42749087935     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.11.004     Document Type: Article

References (43)

1. Bailey S.L., Schreiner B., McMahon E.J., and Miller S.D. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat. Immunol. 8 (2007) 172-180
2. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., and Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
3. Brandt K., Bulfone-Paus S., Jenckel A., Foster D.C., Paus R., and Ruckert R. Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J. Invest. Dermatol. 121 (2003) 1379-1382
4. Collins M., Whitters M.J., and Young D.A. IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol. Res. 28 (2003) 131-140
5. Comes A., Rosso O., Orengo A.M., Di Carlo E., Sorrentino C., Meazza R., Piazza T., Valzasina B., Nanni P., Colombo M.P., and Ferrini S. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176 (2006) 1750-1758
6. Coquet J.M., Kyparissoudis K., Pellicci D.G., Besra G., Berzins S.P., Smyth M.J., and Godfrey D.I. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178 (2007) 2827-2834
7. Ettinger R., Sims G.P., Fairhurst A.M., Robbins R., da Silva Y.S., Spolski R., Leonard W.J., and Lipsky P.E. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175 (2005) 7867-7879
8. Frohlich A., Marsland B.J., Sonderegger I., Kurrer M., Hodge M.R., Harris N.L., and Kopf M. IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood 109 (2007) 2023-2031
9. Herber D., Brown T.P., Liang S., Young D.A., Collins M., and Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J. Immunol. 178 (2007) 3822-3830
10. Huang D., Shi F.D., Jung S., Pien G.C., Wang J., Salazar-Mather T.P., He T.T., Weaver J.T., Ljunggren H.G., Biron C.A., Littman D.R., and Ransohoff R.M. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. Faseb. J. 20 (2006) 896-905
11. Jee Y., and Matsumoto Y. Two-step activation of T cells, clonal expansion and subsequent Th1 cytokine production, is essential for the development of clinical autoimmune encephalomyelitis. Eur. J. Immunol. 31 (2001) 1800-1812
12. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., Johnson K.A., Witek J.S., Senices M., Konz R.F., Wurster A.L., Donaldson D.D., Collins M., Young D.A., and Grusby M.J. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16 (2002) 559-569
13. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., and Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177 (2006) 566-573
14. Koo G.C., and Peppard J.R. Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 3 (1984) 301-303
15. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., Oukka M., and Kuchroo V.K. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448 (2007) 484-487
16. Leonard W.J. Cytokines and immunodeficiency diseases. Nat. Rev. Immunol. 1 (2001) 200-208
17. Leonard W.J., and Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5 (2005) 688-698
18. Liu R., La Cava A., Bai X.F., Jee Y., Price M., Campagnolo D.I., Christadoss P., Vollmer T.L., Van Kaer L., and Shi F.D. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 175 (2005) 7898-7904
19. Liu R., Van Kaer L., La Cava A., Price M., Campagnolo D.I., Collins M., Young D.A., Vollmer T.L., and Shi F.D. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J. Immunol. 176 (2006) 5247-5254
20. Liu J.Q., Carl Jr. J.W., Joshi P.S., RayChaudhury A., Pu X.A., Shi F.D., and Bai X.F. CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J. Immunol. 178 (2007) 6227-6235
21. Lohr J., Knoechel B., Wang J.J., Villarino A.V., and Abbas A.K. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J. Exp. Med. 203 (2006) 2785-2791
22. Mehta D.S., Wurster A.L., Whitters M.J., Young D.A., Collins M., and Grusby M.J. IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. 170 (2003) 4111-4118
23. Mehta D.S., Wurster A.L., and Grusby M.J. Biology of IL-21 and the IL-21 receptor. Immunol. Rev. 202 (2004) 84-95
24. Mendel I., Kerlero de Rosbo N., and Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol. 25 (1995) 1951-1959
25. Ozaki K., Spolski R., Feng C.G., Qi C.F., Cheng J., Sher A., Morse III H.C., Liu C., Schwartzberg P.L., and Leonard W.J. A critical role for IL-21 in regulating immunoglobulin production. Science 298 (2002) 1630-1634
26. Ozaki K., Kikly K., Michalovich D., Young P.R., and Leonard W.J. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11439-11444
27. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., Johnston J., Madden K., Xu W., West J., Schrader S., Burkhead S., Heipel M., Brandt C., Kuijper J.L., Kramer J., Conklin D., Presnell S.R., Berry J., Shiota F., Bort S., Hambly K., Mudri S., Clegg C., Moore M., Grant F.J., Lofton-Day C., Gilbert T., Rayond F., Ching A., Yao L., Smith D., Webster P., Whitmore T., Maurer M., Kaushansky K., Holly R.D., and Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
28. Parrish-Novak J., Foster D.C., Holly R.D., and Clegg C.H. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J. Leukoc. Biol. 72 (2002) 856-863
29. Pelletier M., Bouchard A., and Girard D. In vivo and in vitro roles of IL-21 in inflammation. J. Immunol. 173 (2004) 7521-7530
30. Peluso I., Fantini M.C., Fina D., Caruso R., Boirivant M., MacDonald T.T., Pallone F., and Monteleone G. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J. Immunol. 178 (2007) 732-739
31. Pesce J., Kaviratne M., Ramalingam T.R., Thompson R.W., Urban Jr. J.F., Cheever A.W., Young D.A., Collins M., Grusby M.J., and Wynn T.A. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116 (2006) 2044-2055
32. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
33. Singh A.K., Wilson M.T., Hong S., Olivares-Villagomez D., Du C., Stanic A.K., Joyce S., Sriram S., Koezuka Y., and Van Kaer L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194 (2001) 1801-1811
34. Strengell M., Matikainen S., Siren J., Lehtonen A., Foster D., Julkunen I., and Sareneva T. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J. Immunol. 170 (2003) 5464-5469
35. Strengell M., Sareneva T., Foster D., Julkunen I., and Matikainen S. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J. Immunol. 169 (2002) 3600-3605
36. Thornton A.M., Donovan E.E., Piccirillo C.A., and Shevach E.M. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J. Immunol. 172 (2004) 6519-6523
37. Vollmer T.L., Liu R., Price M., Rhodes S., La Cava A., and Shi F.D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 174 (2005) 2696-2701
38. Wurster A.L., Rodgers V.L., Satoskar A.R., Whitters M.J., Young D.A., Collins M., and Grusby M.J. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J. Exp. Med. 196 (2002) 969-977
39. Young D.A., Hegen M., Ma H.L., Whitters M.J., Albert L.M., Lowe L., Senices M., Wu P.W., Sibley B., Leathurby Y., Brown T.P., Nickerson-Nutter C., Keith Jr. J.C., and Collins M. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56 (2007) 1152-1163
40. Zajonc D.M., Maricic I., Wu D., Halder R., Roy K., Wong C.H., Kumar V., and Wilson I.A. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202 (2005) 1517-1526
41. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., Pise-Masison C.A., Radonovich M.F., Brady J.N., Restifo N.P., Berzofsky J.A., and Leonard W.J. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201 (2005) 139-148
42. Zhang B., Yamamura T., Kondo T., Fujiwara M., and Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186 (1997) 1677-1687
43. Ziegler S.F. FOXP3: of mice and men. Annu. Rev. Immunol. 24 (2006) 209-226